Globus Medical Inc.

GMED

NYSE; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001237831

A

strongest fifth of 305 graded peers in healthcare

rank 30 of 305; percentile 9.5; sampling error 2.8 points; lower is stronger

A B C D E

A, the bull



Scoreboard	
Profitability	C/D percentile 59.2
Solvency	B percentile 26.4
Growth and financing	A/B percentile 17.4
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $5.3B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress, fortress balance sheet
Inputs computable	10 of 13
Graded from	filings received through Feb 24, 2026 266 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$70.52 2026-11-16; market equity $9.5B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 24, 2026

; Government Regulation" above for a summary of certain regulations to which we are subject. Regulatory changes and uncertainty could result in restrictions on our ability to carry on or expand our operations, higher than anticipated costs or lower than anticipated sales. The processes by which 510(k) clearance, grant of a de novo classification request, or PMA approval is obtained can be expensive and lengthy and require the payment of significant fees. The FDA's 510(k) clearance process usually takes from three to twelve months, but may last longer.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 59.2						
Gross profitability	37.4%	32.8%		36.5	346	2025-12-31
Return on invested capital	not computable	9.6%				

one or more required annual facts are missing

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(4.1%)	(6.7%)	65.3	756	2025-12-31
Gross margin stability, five years	6.0 pts	2.8 pts	75.8	237	2025-12-31
Solvency, sleeve percentile 26.4					
Altman Z double-prime	10.06	0.31	8.8	705	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(3.61x)			
one or more required annual facts are missing					
Current ratio	4.26x	2.68x	44.0	781	2025-12-31
Growth and financing, sleeve percentile 17.4					
Revenue growth, three-year compound	42.2%	9.6%	15.0	400	2025-12-31
Free cash flow growth, three-year compound	78.0%	11.1%	8.6	94	2025-12-31
Reinvestment rate	45.4%	33.9%	44.0	101	2025-12-31
Asset growth, three years	36.7%	3.2%	11.9	663	2025-12-31
Net share issuance, one year	(1.7%)	1.6%	7.4	624	2026-02-20

Among 305 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
25	Hims & Hers Health, Inc. (HIMS)	7.9	A	
26	Veracyte, Inc. (VCYT)	8.2	A	
27	Alkermes plc. (ALKS)	8.6	A	
28	Xtant Medical Holdings, Inc. (XTNT)	8.9	A	fortress balance sheet
29	Viemed Healthcare, Inc. (VMD)	9.2	A	
30	Globus Medical Inc. (GMED)	9.5	A	
31	LivaNova plc (LIVN)	9.9	A	fortress balance sheet
32	RxSight, Inc. (RXST)	10.2	A	fortress balance sheet
33	Si-Bone, Inc. (SIBN)	10.5	A	fortress balance sheet
34	TransMedics Group, Inc. (TMDX)	10.9	A	
35	Treace Medical Concepts, Inc. (TMCI)	11.2	A	

What the price implies

at the 2026-11-16 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	24.0%	(1.7%)	66
Distance from 52-week high	(27.2%)	(31.5%)	52
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	6.2%	0.5%	84
Book value to price	0.51	0.28	68
Sales to price	0.31	0.36	44
Composite equity issuance, five years	29.7%	13.2%	65
Relative strength against the sector, log excess return	0.04	(0.19)	66

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Twelve-month failure probability, CHS model	not computable	0.06%

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$441.3M
Operating cash flow, four quarters	$925.9M
Months of runway	not finite
Days since last periodic filing	12 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$107.7M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:Revenues	$2.9B	2025-12-31	2026-02-24	10-K	26-011209
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$957.8M	2025-12-31	2026-02-24	10-K	26-011209
3	assets	us-gaap:Assets	$5.3B	2025-12-31	2026-02-24	10-K	26-011209
4	net income	us-gaap:NetIncomeLoss	$537.9M	2025-12-31	2026-02-24	10-K	26-011209
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$753.4M	2025-12-31	2026-02-24	10-K	26-011209
6	assets	us-gaap:Assets	$5.3B	2024-12-31	2026-02-24	10-K	26-011209
7	revenue	us-gaap:Revenues	$2.5B	2024-12-31	2026-02-24	10-K	26-011209
8	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$1.0B	2024-12-31	2026-02-24	10-K	26-011209
9	gross profit	us-gaap:GrossProfit	$1.0B	2023-12-31	2024-02-21	10-K	24-000032
10	revenue	us-gaap:Revenues	$1.6B	2023-12-31	2026-02-24	10-K	26-011209
11	gross profit	us-gaap:GrossProfit	$759.1M	2022-12-31	2024-02-21	10-K	24-000032
12	revenue	us-gaap:Revenues	$1.0B	2022-12-31	2025-02-20	10-K	25-000026
13	gross profit	us-gaap:GrossProfit	$718.9M	2021-12-31	2024-02-21	10-K	24-000032
14	revenue	us-gaap:Revenues	$958.1M	2021-12-31	2024-02-21	10-K	24-000032
15	current assets	us-gaap:AssetsCurrent	$2.1B	2025-12-31	2026-02-24	10-K	26-011209
16	current liabilities	us-gaap:LiabilitiesCurrent	$498.5M	2025-12-31	2026-02-24	10-K	26-011209
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$1.4B	2025-12-31	2026-02-24	10-K	26-011209
18	operating income	us-gaap:OperatingIncomeLoss	$479.8M	2025-12-31	2026-02-24	10-K	26-011209
19	book equity	us-gaap:StockholdersEquity	$4.6B	2025-12-31	2026-02-24	10-K	26-011209
20	liabilities	us-gaap:Liabilities	$729.5M	2025-12-31	2026-02-24	10-K	26-011209
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$164.7M	2025-12-31	2026-02-24	10-K	26-011209
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$520.6M	2024-12-31	2026-02-24	10-K	26-011209
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$115.4M	2024-12-31	2026-02-24	10-K	26-011209
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$243.5M	2023-12-31	2026-02-24	10-K	26-011209
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$78.3M	2023-12-31	2026-02-24	10-K	26-011209
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$178.5M	2022-12-31	2025-02-20	10-K	25-000026
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$74.0M	2022-12-31	2025-02-20	10-K	25-000026
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$276.8M	2025-12-31	2026-02-24	10-K	26-011209
29	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$605.1M	2025-12-31	2026-02-24	10-K	26-011209
30	income tax	us-gaap:IncomeTaxExpenseBenefit	$67.2M	2025-12-31	2026-02-24	10-K	26-011209

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

31	current assets	us-gaap:AssetsCurrent	$2.2B	2024-12-31	2026-02-24	10-K	26-011209
32	current liabilities	us-gaap:LiabilitiesCurrent	$855.9M	2024-12-31	2026-02-24	10-K	26-011209
33	assets	us-gaap:Assets	$5.1B	2023-12-31	2025-02-20	10-K	25-000026
34	assets	us-gaap:Assets	$2.1B	2022-12-31	2024-02-21	10-K	24-000032
35	shares outstanding	dei:EntityCommonStockSharesOutstanding	135,253,051	2026-02-20	2026-02-24	10-K	26-011209
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	137,541,648	2025-02-18	2025-02-20	10-K	25-000026